Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 2,511 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Breast Cancer
Interventions: Just ASK training; Behavioral
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Plainsboro, New Jersey

Conditions: Healthy Adults
Interventions: Prednisone, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Alpha-Gal Syndrome, Allergy
Interventions: DBFC with 150g of Alpha-gal Knock Out (KO) pork, DBFC with 150g of Wild Type (WT) pork; Diagnostic Test
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years to 50 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 4
States / cities: Little Rock, Arkansas • Chapel Hill, North Carolina • Nashville, Tennessee + 1 more

Conditions: Suicide Risk, Suicide Attempt, Treatment Response
Interventions: Brief Cognitive Behavioral Therapy; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Healthy
Interventions: PF-07328948, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Respiratory Depression
Interventions: Fentanyl; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 80 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Healthy
Interventions: Lu AG06479, Placebos; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Prostate Cancer, Prostatic Neoplasms
Interventions: Not listed
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV Infections
Interventions: Fostemsavir 600 mg, Fostemsavir 200 mg; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Volunteers
Interventions: BMS-986460; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy Volunteers
Interventions: ACP-196, Moxifloxacin 400 mg, Placebo; Drug
Lead sponsor: Acerta Pharma BV; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Pharmacokinetics, Pharmacodynamics
Interventions: I004, NovoLog; Drug
Lead sponsor: Amphastar Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis, Immune System Diseases
Interventions: PVX-108, Placebo; Biological
Lead sponsor: Aravax Pty Ltd; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 8
States / cities: Little Rock, Arkansas • Rolling Hills Estates, California • Atlanta, Georgia + 5 more

Conditions: Blood Coagulation Disorders, Hemophilia A
Interventions: Recombinant Factor VIII (BAY81-8973), Recombinant Factor VIII (Kogenate FS, BAY14-2222); Biological
Lead sponsor: Bayer; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 7
States / cities: Orange, California • Sacramento, California • Tampa, Florida + 4 more

Conditions: MTBI - Mild Traumatic Brain Injury
Interventions: PATH + DigitMemory (DM) neurotraining; Behavioral
Lead sponsor: Perception Dynamics Institute; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: San Diego, California • Solana Beach, California

Conditions: Healthy
Interventions: Palbociclib alone, Palbociclib + Rabeprazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Motor Learning
Interventions: Motor Imagery (MI), Active tDCS, Sham tDCS; Behavioral · Device
Lead sponsor: Appalachian State University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Boone, North Carolina

Conditions: Sickle Cell Disease, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
Interventions: autologous bone marrow derived CD34+ HSPCs electroporated with BCL11A enhancer targeting Cas9 ribonucleoprotein, Sequencing Assay for Variant rs114518452; Biological · Device
Lead sponsor: Daniel Bauer; Other
Eligibility: 13 Years to 35 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pre-Gestational Diabetes, Type2diabetes, Pregnancy in Diabetic, Pregnancy, High Risk
Interventions: DEXCOM G7 PRO Continuous Glucose Monitor, Patient mHealth app linked to a provider dashboard, Care team coaching for medical and social needs (HUB), Provider dashboard; Device · Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Pharmacokinetics
Interventions: Natrunix, Placebo; Biological
Lead sponsor: XBiotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Autism Spectrum Disorder
Interventions: Anatomical MRI Scan; Diagnostic Test
Lead sponsor: San Diego State University; Other
Eligibility: 40 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: San Diego, California

Conditions: Genetic Conditions, Genetic Disorders
Interventions: RNA sequencing; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 2 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetes Mellitus, Type 1
Interventions: TOL-3021, TOL-3021 Placebo; Biological · Other
Lead sponsor: Tolerion, Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 23
States / cities: San Diego, California • San Francisco, California • San Mateo, California + 20 more

Conditions: Rheumatoid Arthritis
Interventions: sarilumab SAR153191 (REGN88), simvastatin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Duncansville, Pennsylvania • Jackson, Tennessee • Dallas, Texas

Search by objective public record fields.

A Pilot Trial of "Just ASK™" to Increase Discussions About Breast Cancer Clinical Trials

The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy Volunteers

Beginning to Assess an Appropriate CONtrol for Oral Food Challenges in Alpha-Gal Syndrome (CoFAR-13) - BeACON4AG

Study to Refine the Effectiveness of New Generation Therapies for Suicide

A Study to Learn How Different Amounts of the Study Medicine Called PF-07328948 Are Tolerated and Act in the Body in Healthy Adults

Precision Medicine in Anesthesia: Genetic Component in Opioid-induced Respiratory Depression

Safety and Tolerability of Lu AG06479 in Healthy Young Men

Study of Prostate Cancer in Black and White U.S. Veterans

Low-dose Fostemsavir Extended Release Relative Bioavailability Study

A Single-dose Study to Evaluate the Safety, Tolerability, Drug Levels, and Relative Biological Availability of Alternate Formulations of BMS-986460 in Healthy Adult Male Participants

A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers

A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A

Retraining Neural Pathways Improves Cognitive Skills After A Mild Traumatic Brain Injury

Drug Interaction Study To Investigate The Potential Effect Of Proton Pump Inhibitor On The Pharmacokinetics Of Palbociclib (PD-0332991)

Improving Locomotor Learning With Brain Stimulation

Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Sickle Cell Disease

Successfully Achieving and Maintaining Euglycemia During Pregnancy for Type 2 Diabetes Through Technology and Coaching

Safety and Pharmacokinetics (PK) Study of Natrunix in Healthy Volunteers

Age-related Changes in Myeloarchitectonics Across Adulthood in Autism Spectrum Disorder

RNA to the RESCUE: Evaluation to Assess the Clinical Utility of RNA Sequencing in Establishing a Genetic Diagnosis or Adjudicating a Previously Established Genetic Diagnosis.

Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients

Sarilumab Effect on the Pharmacokinetics of Simvastatin